Skip to main content
SpringerLink
Log in

Gemigliptin, a novel dipeptidyl peptidase 4 inhibitor: first new anti-diabetic drug in the history of Korean pharmaceutical industry

  • Report on Investigational Drugs
  • Published:
Archives of Pharmacal Research Aims and scope Submit manuscript

Abstract

Gemigliptin, a potent, selective and long-acting DPP 4 inhibitor was developed by LG Life Sciences and approved for use in patients with type 2 diabetes mellitus by the Korean Food and Drug Administration in June 2012 under the trade name Zemiglo®. Clinical pharmacokinetic and pharmacodynamic data suggest the efficacy and once daily dosing of gemigliptin. In clinical phase III studies, gemigliptin was efficacious as either monotherapy or combination therapy (add-on to metformin) and well tolerated in patients with type 2 diabetes. Further development of combination therapy is on-going.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  • Cefalu, W.T., and S. Urquhart. 2007. Clinical management strategies for type 2 diabetes. Journal of the American Academy of Physician Assistants Suppl: 9–14.

    Article  PubMed  Google Scholar 

  • Drucker, D.J. 2007. Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: preclinical biology and mechanisms of action. Diabetes Care 30: 1335–1343.

    Article  PubMed  CAS  Google Scholar 

  • Hwang, D.M., S.H. Kim, M.K. Yoon, O.H. Kwon, K.D. Koo, C.H. Min, S.H. Lee, J.I. Lee, C.S. Lee, H.J. Yim. 2008. LC15-0444 is a novel, potent, selective, and orally active dipeptidyl peptidase IV inhibitor. Poster presented at the annual meeting of American Diabetes Association. San Francisco: CA.

  • Kim, S.E., S. Yi, K.H. Shin, T.E. Kim, M.J. Kim, Y.H. Kim, S.H. Yoon, J.Y. Cho, S.G. Shin, I.J. Jang, and K.S. Yu. 2012. Evaluation of the pharmacokinetic interaction between the dipeptidyl peptidase IV inhibitor LC15-0444 and pioglitazone in healthy volunteers. International Journal of Clinical Pharmacology and Therapeutics 50: 17–23.

    Article  PubMed  CAS  Google Scholar 

  • Lankas, G.R., B. Leiting, R.S. Roy, G.J. Eiermann, M.G. Beconi, T. Biftu, C.C. Chan, S. Edmondson, W.P. Feeney, H. He, D.E. Ippolito, D. Kim, S.K.A. Lyon, H.O. Ok, R.A. Patel, A.N. Petrov, K.A. Pryor, X. Qian, L. Reigle, A. Woods, J.K. Wu, D. Zaller, X. Zhang, L. Zhu, A.E. Weber, and N.A. Thornberry. 2005. Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: Potential importance of selectivity over dipeptidyl peptidases 8 and 9. Diabetes 54: 2988–2994.

    Article  PubMed  CAS  Google Scholar 

  • Lim, K.S., J.Y. Cho, B.H. Kim, J.R. Kim, H.S. Kim, D.K. Kim, S.H. Kim, H.J. Yim, S.H. Lee, S.G. Shin, I.J. Jang, and K.S. Yu. 2009. Pharmacokinetics and pharmacodynamics of LC15-0444, a novel dipeptidyl peptidase IV inhibitor, after multiple dosing in healthy volunteers. British Journal of Clinical Pharmacology 68: 883–890.

    Article  PubMed  CAS  Google Scholar 

  • Lim, K.S., J.R. Kim, Y.J. Choi, K.H. Shin, K.P. Kim, J.H. Hong, J.Y. Cho, H.S. Shin, K.S. Yu, S.G. Shin, O.H. Kwon, D.M. Hwang, J.A. Kim, and I.J. Jang. 2008. Pharmacokinetics, pharmacodynamics, and tolerability of the dipeptidyl peptidase IV inhibitor LC15-0444 in healthy Korean men: A dose-block-randomized, double-blind, placebo-controlled, ascending single-dose. Phase I study. Clinical Therapeutics 30: 1817–1830.

    Article  PubMed  CAS  Google Scholar 

  • Noh, Y.H., H.S. Lim, S.J. Jin, M.J. Kim, Y.H. Kim, H.R. Sung, H.Y. Choi, and K.S. Bae. 2012. Effects of ketoconazole and rifampicin on the pharmacokinetics of gemigliptin, a dipeptidyl peptidase-IV inhibitor: A crossover drug–drug interaction study in healthy male Korean volunteers. Clinical Therapeutics 34: 1182–1194.

    Article  PubMed  CAS  Google Scholar 

  • Ohnuma, K., N.H. Dang, and C. Morimoto. 2008. Revisiting an old acquaintance: CD26 and its molecular mechanisms in T cell function. Trends in Immunology 29: 295–301.

    Article  PubMed  CAS  Google Scholar 

  • Rhee, E.J., W.Y. Lee, K.H. Yoon, S.J. Yoo, I.K. Lee, S.H. Baik, Y.K. Kim, M.K. Lee, K.S. Park, J.Y. Park, B.S. Cha, H.W. Lee, K.W. Min, H.Y. Bae, M.J. Kim, J.A. Kim, D.K. Kim, and S.W. Kim. 2010. A multicenter, randomized, placebo-controlled, double-blind phase II trial evaluating the optimal dose, efficacy and safety of LC 15–0444 in patients with type 2 diabetes. Diabetes Obesity and Metabolism 12: 1113–1119.

    Article  CAS  Google Scholar 

  • Rhee, E.J., W.Y. Lee, K.W. Min, V.K. Shivane, A.R. Sosale, H.C. Jang, C.H. Chung, I.S. Nam-Goong, J.A. Kim, S.W. Kim. Gemigliptin Study 006 Group. 2013. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor gemigliptin compared with sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Obesity and Metabolism 15: 523–530.

    Google Scholar 

  • Yang, S.J., K.W. Min, S.K. Gupta, J.Y. Park, V.K. Shivane, S.U. Pitale, P.K. Agarwal, A. Sosale, P. Gandhi, M. Dharmalingam, V. Mohan, U. Mahesh, D.M. Kim, Y.S. Kim, J.A. Kim, P.K. Kim, S.H. Baik. 2012. A multicentre, multinational, randomized, placebo-controlled, double-blind, phase 3 trial to evaluate the efficacy and safety of gemigliptin (LC15-0444) in patients with type II diabetes. Diabetes Obesity and Metabolism 15: 410–416.

    Google Scholar 

Download references

Acknowledgments

This study was partially supported by a grant from the Ministry of Knowledge Economy (Bio-Star, 10024075).

Author information

Authors and Affiliations

  1. LG Life Science R&D Park, 104-1, Munji-dong, Yuseong-gu, Daejeon, 305-380, Korea

    Sung-Ho Kim, Sung-Hack Lee & Hyeon-Joo Yim

Authors
  1. Sung-Ho Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sung-Hack Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hyeon-Joo Yim
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hyeon-Joo Yim.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kim, SH., Lee, SH. & Yim, HJ. Gemigliptin, a novel dipeptidyl peptidase 4 inhibitor: first new anti-diabetic drug in the history of Korean pharmaceutical industry. Arch. Pharm. Res. 36, 1185–1188 (2013). https://doi.org/10.1007/s12272-013-0171-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12272-013-0171-x

Keywords

Search

Navigation